saccharomyces boulardii and Reduced Flatulence

Safety in these studies

abdominal distentionReported4.9% vs. 12.7%, RR = 0.41, 95% CI: 0.23-0.72, p = 0.002
abdominal distention (4.9% vs. 12.7%, RR = 0.41, 95% CI: 0.23-0.72, p = 0.002)
from: The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for
constipationReported2.9% vs. 8.4%, RR = 0.35, 95% CI: 0.14-0.88, p = 0.03
constipation (2.9% vs. 8.4%, RR = 0.35, 95% CI: 0.14-0.88, p = 0.03)
from: The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for
diarrheaReported7.9% vs. 25.7%, RR = 0.29, 95% CI: 0.17-0.48, p < 0.00001
diarrhea (7.9% vs. 25.7%, RR = 0.29, 95% CI: 0.17-0.48, p < 0.00001)
from: The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for
overall adverse eventsReported22% vs. 39%, RR = 0.56, 95% CI: 0.44-0.70, p < 0.00001
The combination of S. boulardii and BQT had a significantly lower rate of overall adverse events (22% vs. 39%, RR = 0.56, 95% CI: 0.44-0.70, p < 0.00001)
from: The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for

1 of 1 paper

The effect of supplementing with Saccharomyces boulardii on bismuth quadruple therapy for eradicating Helicobacter pylori: a systematic review and meta-analysis of randomized controlled trials.